Molecular Mechanism of the Additive Effects of Leukotriene Modifier in Asthmatic Patients Receiving Steroid Therapy
-
- Matsunaga Kazuto
- Third Department of Internal Medicine, Wakayama Medical University, School of Medicine
-
- Yanagisawa Satoru
- Third Department of Internal Medicine, Wakayama Medical University, School of Medicine
-
- Ichikawa Tomohiro
- Third Department of Internal Medicine, Wakayama Medical University, School of Medicine
-
- Akamatsu Keiichiro
- Third Department of Internal Medicine, Wakayama Medical University, School of Medicine
-
- Koarai Akira
- Third Department of Internal Medicine, Wakayama Medical University, School of Medicine
-
- Hirano Tsunahiko
- Third Department of Internal Medicine, Wakayama Medical University, School of Medicine
-
- Sugiura Hisatoshi
- Third Department of Internal Medicine, Wakayama Medical University, School of Medicine
-
- Minakata Yoshiaki
- Third Department of Internal Medicine, Wakayama Medical University, School of Medicine
-
- Ichinose Masakazu
- Third Department of Internal Medicine, Wakayama Medical University, School of Medicine
この論文をさがす
抄録
Background: The addition of leukotriene modifier (LM) may be a useful approach for uncontrollable asthma despite treatment with inhaled corticosteroid (ICS), especially in asthmatics comorbid with allergic rhinitis (AR), although little is known about its molecular mechanism. We evaluated the additive effects of LM with ICS on pulmonary function and airway inflammation in asthmatics with or without AR.<br> Methods: Eighteen uncontrolled steroid-treated asthmatics, nine with and nine without AR, were enrolled. Spirometry, peak expiratory flow (PEF) measurements, and exhaled breath condensate sampling were performed before and 8 weeks after LM administration. The lowest PEF over the course of one week, expressed as a percentage of the highest PEF (Min%Max PEF), was used as an index of fluctuation of the airway caliber. Airway cytokine expression was analyzed with a protein array.<br> Results: A significant improvement in forced expiratory volume in one second as a percentage of the predicted value (%FEV1) and Min%Max PEF was seen in the subgroup of asthma with AR. Although there was no significant difference in the baseline cytokine values between the groups, the exhaled RANTES level was significantly reduced by LM in the asthma with AR group. The changes in the RANTES level were significantly related to the changes in the %FEV1 and Min%Max PEF values.<br> Conclusions: LM caused a greater improvement in pulmonary function and airway inflammation in asthmatics with AR. The RANTES-mediated pathway may be involved in the improvement of the airflow limitation and airway lability by LM additive therapy in asthmatics receiving steroid therapy.<br>
収録刊行物
-
- Allergology International
-
Allergology International 58 (1), 89-96, 2009
一般社団法人日本アレルギー学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282679608364416
-
- NII論文ID
- 10025109202
- 130004477024
-
- NII書誌ID
- AA11091750
-
- ISSN
- 14401592
- 13238930
-
- PubMed
- 19153534
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可